Back to Search Start Over

Coya: Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease

Source :
Entertainment Close-up. September 27, 2024
Publication Year :
2024

Abstract

Coya Therapeutics, a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, reported the direct CNS anti-inflammatory effect of subcutaneously administered COYA 302 in a preclinical [...]

Subjects

Subjects :
T cells
Diseases
Anti-inflammatory drugs
Arts and entertainment industries

Details

Language :
English
Database :
Gale General OneFile
Journal :
Entertainment Close-up
Publication Type :
Periodical
Accession number :
edsgcl.810342908

Tools

Authors Abstract Subjects Details